PMA vs 510(k): Differences, Requirements, and How to Choose the Right FDA Pathway

Why This Comparison Matters

Choosing the wrong FDA pathway does not simply delay your submission — it can cost you a year or more of development time, millions of dollars in unnecessary clinical trials, or a Refuse to Accept (RTA) letter that forces you to start over. A digital cardiac monitoring startup that submitted a 510(k) for a Class III device had to rerun trials and refile after receiving a Not Substantially Equivalent (NSE) determination, losing over 14 months of market time and exhausting a significant portion of its Series A funding.

The premarket approval (PMA) and 510(k) premarket notification pathways are the two primary routes through which medical devices reach the US market. They differ in legal basis, evidentiary standard, clinical requirements, review timeline, cost, and post-market obligations. Understanding these differences at the strategic level — not just the procedural level — is what separates a regulatory plan that works from one that collapses under FDA scrutiny.

This guide provides a comprehensive, side-by-side comparison of the PMA and 510(k) pathways, introduces the De Novo pathway as a critical third option, and gives you a practical decision framework for choosing the right route for your device.

FDA Device Classification: The Foundation for Pathway Selection

Before comparing PMA and 510(k), you must understand how the FDA classifies medical devices. The classification determines which regulatory pathway applies. The FDA recognizes three device classes under the FD&C Act, based on the level of regulatory control needed to ensure safety and effectiveness.

Class I — General Controls (Low Risk)

Class I devices pose the lowest risk to patients. They are subject to "general controls" — the baseline regulatory requirements that apply to all medical devices, including establishment registration, device listing, good manufacturing practices, labeling, and adverse event reporting. Approximately 47% of all medical device types fall into Class I, and the vast majority (roughly 95%) are exempt from the 510(k) requirement.

Examples of Class I devices: tongue depressors, elastic bandages, examination gloves, manual stethoscopes, shoe covers, handheld surgical instruments (scalpels, forceps), and bedpans.

Class II — General Controls + Special Controls (Moderate Risk)

Class II devices carry moderate risk and require "special controls" in addition to general controls. Special controls can include performance standards, post-market surveillance requirements, patient registries, device-specific FDA guidance documents, and mandatory labeling requirements. Class II devices represent the largest category — approximately 43% of all device types. Most Class II devices require 510(k) clearance before marketing, though some are 510(k)-exempt.

Examples of Class II devices: powered wheelchairs, infusion pumps, pregnancy test kits, blood pressure cuffs, contact lenses, surgical drapes, CT scanners, pulse oximeters, non-absorbable sutures, catheter introducers, orthopedic casting materials, and most Software as a Medical Device (SaMD) products.

Class III — General Controls + Special Controls + Premarket Approval (High Risk)

Class III devices are the highest risk category. These are devices that sustain or support life, are implanted in the body, or present a potential unreasonable risk of illness or injury. Class III devices represent approximately 10% of all device types and almost always require PMA approval before marketing (unless a pre-amendment exception applies).

Examples of Class III devices: implantable pacemakers, coronary drug-eluting stents, heart valves (mechanical and tissue), cochlear implants, implantable cardioverter-defibrillators (ICDs), breast implants (silicone), total hip and knee replacement systems, ventilators (life-supporting), high-risk IVDs (HIV screening tests, companion diagnostics), and implantable neurostimulators.

How Classification Determines Your Pathway

Device Class	Typical Pathway	Exception
Class I (non-exempt)	510(k)	Most Class I devices are 510(k)-exempt
Class II	510(k)	Novel Class II with no predicate → De Novo
Class III	PMA	Pre-amendment Class III without a call-for-PMA order → 510(k); novel low-to-moderate risk → De Novo

Practical tip: To determine your device's classification, search the FDA's Product Classification Database (accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm) using keywords, product code, or device panel. The database entry will tell you the device class, product code, regulation number, and what type of premarket submission is required. If your device does not match any existing product code, it is automatically classified as Class III under Section 513(f)(1) — but De Novo may be the appropriate route if the risk is low to moderate.

At a Glance: 510(k) vs. PMA

Before diving into the details, here is the executive summary for decision-makers who need the bottom line quickly.

510(k) — Premarket Notification is a comparative pathway. You show the FDA that your device is substantially equivalent to something already on the market. It is faster (median ~130 calendar days), cheaper (total cost typically $50K-$500K), and does not require clinical trials in most cases. Most Class II devices go through 510(k). The FDA "clears" your device — it does not "approve" it.

PMA — Premarket Approval is an independent pathway. You present clinical and scientific evidence proving your device is safe and effective, without reference to another device. It is slower (typically 3-7+ years including clinical trials), dramatically more expensive (total cost typically $5M-$75M+), and nearly always requires a pivotal clinical trial under an IDE. Class III devices go through PMA. The FDA "approves" your device.

De Novo — Classification Request is a pathway for novel, low-to-moderate risk devices that have no predicate. It creates a new classification regulation and allows future devices of the same type to use the 510(k) pathway. Costs and timelines fall between 510(k) and PMA.

The remainder of this guide unpacks every dimension of these pathways in detail.

Legal Foundation: Where Each Pathway Comes From

Both pathways originate from the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device Amendments of 1976. Understanding the statutory basis of each pathway clarifies why they function so differently.

510(k) — Section 510(k) of the FD&C Act

The 510(k) premarket notification is codified in Section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and implemented through 21 CFR Part 807, Subpart E. It requires manufacturers to notify the FDA at least 90 days before marketing a device and demonstrate that the device is substantially equivalent to a legally marketed predicate device.

The legal standard is substantial equivalence — not safety and effectiveness in the absolute sense. The FDA asks: "Is this device at least as safe and effective as a device that is already legally on the market?" If the answer is yes, the device is "cleared" (not "approved").

PMA — Section 515 of the FD&C Act

The PMA pathway is codified in Section 515 of the FD&C Act (21 U.S.C. 360e) and implemented through 21 CFR Part 814. It requires manufacturers to submit an application demonstrating a reasonable assurance of safety and effectiveness based on valid scientific evidence — typically including clinical trial data.

The legal standard is higher and independent. The FDA does not compare your device to another device already on the market. Instead, it evaluates the totality of evidence — bench testing, animal studies, clinical trials, manufacturing information — and makes an independent determination that the device is safe and effective for its intended use. If it passes this scrutiny, the device is "approved."

Why the Distinction Matters

The difference between "cleared" and "approved" is not semantic. A 510(k) clearance means the FDA found your device substantially equivalent to a predicate — it does not independently validate safety and effectiveness. A PMA approval means the FDA reviewed your evidence and affirmatively concluded the device is safe and effective. This distinction affects your labeling (you cannot claim "FDA approved" for a 510(k)-cleared device), your marketing materials, your reimbursement strategy, and how international regulators view your US authorization.

Practical tip: Using the term "FDA approved" for a 510(k)-cleared device is a violation of the FD&C Act and can trigger FDA enforcement action — including warning letters and injunctions. Train your marketing and sales teams on this distinction before commercial launch.

The Comprehensive Comparison Table

The table below compares PMA and 510(k) across every dimension that matters for regulatory planning. Where relevant, the De Novo pathway is included as a third column.

Dimension	510(k)	PMA	De Novo
Legal basis	Section 510(k), FD&C Act	Section 515, FD&C Act	Section 513(f)(2), FD&C Act
Implementing regulation	21 CFR Part 807, Subpart E	21 CFR Part 814	21 CFR Part 860, Subpart D
Standard of review	Substantial equivalence to a predicate	Reasonable assurance of safety and effectiveness	Reasonable assurance of safety and effectiveness
Result	"Cleared"	"Approved"	"Granted" (classified into Class I or II)
Typical device class	Class II (some Class I non-exempt)	Class III	Novel Class I or II (no predicate exists)
Predicate device required?	Yes — must identify a legally marketed predicate	No	No (device becomes the predicate for future 510(k)s)
Clinical data required?	Sometimes (~10-15% of submissions)	Almost always (pivotal clinical trial typical)	Often (depends on device risk and novelty)
IDE clinical trial typically needed?	Rarely	Yes (significant risk devices require IDE approval)	Sometimes
FY2026 user fee (standard)	$26,067	$579,272	$173,782
FY2026 user fee (small business)	$6,517	$144,818	$43,446
First PMA/De Novo fee waiver available?	N/A	Yes (if gross receipts ≤ $30M)	Yes (if gross receipts ≤ $30M)
FDA review goal (MDUFA V)	90 FDA days (95% target)	180 FDA days (statutory); 285 calendar days total (shared MDUFA V goal)	150 FDA days (70% target)
Median total time to decision	~130 calendar days	~12-18 months (with clinical hold time often longer)	~250 calendar days
Submission format	eSTAR (mandatory since Oct 2023)	eCopy; modular review available	eSTAR (mandatory since Oct 2025)
FDA facility inspection before decision?	Not required (may occur post-clearance)	Yes — pre-approval inspection of manufacturing site and QMS	Not typically required
Advisory panel review?	No	Yes for first-of-a-kind devices; discretionary for subsequent	No
Third-party review option?	Yes (3P510k program for eligible device types)	No	No
Annual reporting requirement?	No	Yes — PMA annual report (21 CFR 814.84)	No
Post-market surveillance order likely?	Rare	More common (Section 522 orders)	Possible
Change management mechanism	New 510(k) or letter-to-file	PMA supplement (panel-track, 180-day, real-time, special, or 30-day notice)	New 510(k) or letter-to-file (once classified)
Total cost to market (typical estimate)	$50K-$500K (regulatory + testing)	$5M-$75M+ (including clinical trials)	$200K-$3M+
Breakthrough Device Designation available?	Yes	Yes	Yes
Number of authorizations per year	~3,200-3,500 clearances	~40-60 original approvals	~50-80 grants

Substantial Equivalence vs. Reasonable Assurance

These two evidentiary standards represent fundamentally different questions the FDA is asking — and understanding them is essential to choosing the right pathway.

Substantial Equivalence (510(k))

To demonstrate substantial equivalence under 21 CFR 807.87, you must show that your device, compared to the predicate:

1. Has the same intended use — The indications for use must be the same as, or a subset of, the predicate's indications for use.
2. Has the same technological characteristics — OR, if different technological characteristics exist, that those differences do not raise new questions of safety and effectiveness, and the device is at least as safe and effective as the predicate.

The burden of proof is comparative. You are not proving your device is safe and effective in absolute terms — you are proving it is equivalent to something the FDA has already allowed on the market.

If the FDA determines your device is Not Substantially Equivalent (NSE), it is automatically classified as Class III and cannot be marketed without either a PMA or a successful De Novo classification request.

Reasonable Assurance of Safety and Effectiveness (PMA)

The PMA standard, defined in Section 515(d) of the FD&C Act and interpreted through 21 CFR 860.7, requires valid scientific evidence demonstrating that the device is safe and effective for its intended use under the conditions of use prescribed, recommended, or suggested in the labeling.

"Valid scientific evidence" includes well-controlled investigations, partially controlled studies, studies and objective trials without matched controls, well-documented case histories conducted by qualified experts, and reports of significant human experience with a marketed device. In practice, for most original PMAs, this means a pivotal clinical trial conducted under an approved Investigational Device Exemption (IDE).

The burden of proof is absolute and independent. You must affirmatively demonstrate safety and effectiveness — not merely show equivalence to another device.

Practical tip: If your device has no predicate but is low-to-moderate risk, do not default to PMA. The De Novo pathway under Section 513(f)(2) allows you to demonstrate reasonable assurance of safety and effectiveness and get classified into Class I or II — avoiding the full PMA cost and timeline while creating a new classification regulation for your device type.

Clinical Data Requirements: A Detailed Comparison

Clinical data is the single biggest cost and timeline differentiator between the two pathways.

510(k) Clinical Data

Clinical data is not required for most 510(k) submissions. Approximately 10-15% of 510(k) submissions include clinical data. When clinical data is needed, it is typically because:

• The device has a new intended use or indication that cannot be supported by bench testing alone
• The device type has a device-specific FDA guidance document that calls for clinical data
• The technological differences from the predicate raise questions of biocompatibility or performance that bench and animal testing cannot resolve
• The device is an implant with long-term tissue contact where clinical performance data adds to the safety argument

When clinical data is included in a 510(k), it often takes the form of:

• A literature review of published clinical evidence for the predicate or similar devices
• A retrospective analysis of post-market data
• A small prospective clinical study (not necessarily under an IDE if the study qualifies as non-significant risk)

PMA Clinical Data

Clinical data is required for virtually all original PMA submissions. The typical PMA includes a pivotal clinical study — a prospective, controlled (or historically controlled) investigation conducted under an FDA-approved Investigational Device Exemption (IDE).

Key elements of PMA clinical trials:

• IDE application — Required for significant-risk device studies (21 CFR Part 812). The IDE must be approved by the FDA before enrolling patients. Non-significant risk studies require only IRB approval.
• Study design — Randomized controlled trials (RCTs) are preferred but not always required. The FDA may accept single-arm studies with objective performance criteria (OPC), historical controls, or Bayesian adaptive designs depending on the device type and available evidence.
• Enrollment — PMA clinical trials typically enroll 150 to over 1,000 patients, depending on the endpoint, the disease prevalence, and the acceptable margins for safety and efficacy.
• Follow-up — Minimum follow-up periods range from 6 months to 5+ years for implantable devices. The FDA may require ongoing follow-up as a condition of approval (post-approval study).
• Multi-center design — Most PMA pivotal trials are conducted at 10-50+ clinical sites.
• Cost — Clinical trials represent 40-60% of total PMA development cost. A typical pivotal trial for a Class III device costs $5M-$50M+ depending on complexity, enrollment targets, and follow-up duration.

Comparison Table: Clinical Evidence

Clinical Element	510(k)	PMA
Clinical data required?	Sometimes (~10-15%)	Almost always
IDE needed?	Rarely (only if significant-risk study is conducted)	Yes (for significant-risk studies)
Typical study type	Literature review, retrospective data, or small prospective study	Prospective pivotal trial (RCT or single-arm with OPC)
Typical enrollment	20-100 patients (if any)	150-1,000+ patients
Typical follow-up	3-12 months (if any)	6 months to 5+ years
Estimated clinical cost	$0-$500K	$5M-$50M+
Post-market study required?	Rarely	Often (as condition of approval)

Non-Clinical Testing Requirements: What You Must Generate Before Submission

Beyond clinical data, both pathways require non-clinical (bench) testing — but the scope, depth, and FDA scrutiny differ significantly.

510(k) Non-Clinical Testing

Non-clinical testing for a 510(k) is driven by the comparison to the predicate. You must generate enough data to demonstrate that any differences between your device and the predicate do not raise new questions of safety and effectiveness. Typical testing categories include:

• Performance testing — Functional testing that mirrors the predicate's testing profile. For example, if your predicate's 510(k) summary describes tensile strength testing, you should perform equivalent testing and show comparable or superior results.
• Biocompatibility — If your device contacts the patient (skin, tissue, blood, etc.), you need biocompatibility testing per ISO 10993 series. The extent depends on the nature and duration of contact. A biological evaluation plan and risk assessment may suffice if you can justify a reduced testing program based on material equivalence to the predicate.
• Electrical safety and EMC — For electrically powered devices, testing to IEC 60601-1 (general safety) and IEC 60601-1-2 (electromagnetic compatibility) is expected.
• Software documentation — If your device includes software, you must provide software documentation per the FDA's guidance "Content of Premarket Submissions for Device Software Functions" and IEC 62304 software lifecycle documentation proportional to the software's level of concern.
• Sterilization validation — For sterile devices, demonstrate that your sterilization process achieves the required Sterility Assurance Level (SAL).
• Shelf life / packaging validation — Demonstrate that your device maintains its safety and performance characteristics through its labeled shelf life.

The key principle: your testing program should mirror what the FDA has previously required for your device type. Review the 510(k) summaries of your predicate and related devices to calibrate your testing strategy.

PMA Non-Clinical Testing

PMA non-clinical testing is substantially more extensive because there is no predicate comparison to lean on. The FDA evaluates your testing on its own merits. Typical requirements include everything listed above for 510(k), plus:

• Comprehensive bench testing — Full characterization of all device performance parameters, not just those needed for a predicate comparison. Fatigue testing, accelerated aging, corrosion testing, wear debris analysis, and mechanical reliability testing are common for implantable devices.
• Animal studies — Preclinical animal testing is frequently required for Class III devices, particularly implants. Animal studies may include biocompatibility, chronic implantation, and functional performance evaluation in an animal model. The FDA's IDE review will evaluate whether your animal data adequately supports progression to human clinical trials.
• Computational modeling — For complex devices (e.g., structural heart implants, orthopedic implants), the FDA may expect or accept computational modeling (finite element analysis, computational fluid dynamics) as part of the evidence package.
• Cadaveric or simulated-use testing — For surgical devices, testing in cadaveric models or high-fidelity simulators to evaluate deployment, usability, and procedural risks.

Practical tip: For both pathways, review the device-specific FDA guidance document for your product code before designing your testing program. These guidance documents specify the exact performance tests the FDA expects. If no device-specific guidance exists, the recognized consensus standards listed in the FDA's Standards Database provide the framework.

The Review Process: Step by Step

510(k) Review Process

1. Pre-Submission (Q-Sub) meeting (optional but recommended) — Submit questions to the FDA about predicate selection, testing strategy, clinical requirements. The FDA provides written feedback, typically within 75 days of receipt. No user fee for Pre-Submissions.

2. Prepare submission — Compile device description, intended use/indications for use, predicate comparison, substantial equivalence discussion, performance testing data, biocompatibility data (if applicable), software documentation (if applicable), sterility data (if applicable), labeling, and 510(k) summary or statement.

3. Submit via eSTAR — All 510(k) submissions must use the electronic Submission Template and Resource (eSTAR) format. Pay the user fee ($26,067 standard / $6,517 small business for FY2026).

4. Acceptance review (15 days) — The FDA screens the submission using the Refuse to Accept (RTA) checklist. If the submission is incomplete, FDA issues an RTA letter and the submission is returned. The RTA rate for 510(k)s has historically been 15-25%.

5. Substantive review (up to 90 FDA days) — An FDA reviewer evaluates the technical content. The reviewer may issue an Additional Information (AI) request, which stops the review clock until you respond. Common AI topics: predicate justification, additional testing data, labeling changes, software documentation gaps.

6. Decision — The FDA issues one of three outcomes:

   • Substantially Equivalent (SE) — Device is cleared. You receive a clearance letter and a 510(k) number (e.g., K241234).
   • Not Substantially Equivalent (NSE) — Device is not cleared. It is automatically classified as Class III. You may pursue a De Novo or PMA.
   • Withdrawal — You withdraw the submission voluntarily (e.g., to address major deficiencies and resubmit).

Types of 510(k) Submissions

Not all 510(k) submissions are the same. The FDA offers three distinct types, each designed for different situations. Choosing the right type affects your review timeline, documentation burden, and likelihood of clearance.

Traditional 510(k) — The standard and most common submission type, accounting for approximately 79% of all 510(k) filings. Use this type when you are introducing a device that has never been cleared before, or when a modification to a previously cleared device does not qualify for the Special 510(k) pathway. A Traditional 510(k) requires the most comprehensive documentation package, including full performance data, predicate comparison, and all supporting evidence. The FDA review goal is 90 FDA days.

Special 510(k) — An expedited pathway for manufacturers modifying their own previously cleared device, where the modification does not affect the intended use and the design control process produces reliable results that form the basis for the substantial equivalence determination. The key advantage is a 30-day FDA review target — significantly faster than the Traditional 510(k). To qualify, the modification must be to your own cleared device (not a competitor's predicate), and you must have a documented design control process that evaluated the change. Common qualifying modifications include design improvements, manufacturing process updates, or material changes where the intended use remains identical. You submit your design control documentation (risk analysis, verification and validation results) rather than a full predicate comparison.

Abbreviated 510(k) — An alternative pathway where you demonstrate substantial equivalence by relying on FDA guidance documents, recognized consensus standards, or special controls established for your device type, rather than through a direct device-to-predicate comparison. If an FDA-recognized standard fully covers the performance characteristics of your device, you can demonstrate compliance with that standard rather than generating comparative bench testing data against a specific predicate. The review goal is 90 FDA days, the same as a Traditional 510(k), but the submission may be leaner because the compliance data is structured around standards rather than a point-by-point predicate comparison.

510(k) Type	When to Use	Review Goal	Key Requirement
Traditional	New device or significant change not qualifying for Special	90 FDA days	Full predicate comparison with performance data
Special	Modification to your own cleared device	30 FDA days	Design control documentation; same intended use
Abbreviated	Device covered by guidance documents, standards, or special controls	90 FDA days	Compliance with recognized standards or special controls

Practical tip: Do not default to a Traditional 510(k) when a Special 510(k) would suffice. The 30-day review target for Special 510(k) submissions can save 2-3 months of calendar time. However, Special 510(k) is only available for modifications to your own cleared device — you cannot use a competitor's clearance as the predicate for a Special 510(k).

PMA Review Process

1. Pre-Submission (Q-Sub) meetings (strongly recommended, often multiple) — Discuss study design, endpoints, enrollment, device description, manufacturing information. The FDA provides detailed written feedback. For complex devices, manufacturers may have 3-5 or more Pre-Submission interactions before filing the PMA.

2. IDE application (if clinical study required) — Submit IDE application for significant-risk studies. FDA has 30 days to approve, approve with conditions, or disapprove. Conduct clinical trial at approved sites under IRB oversight.

3. Prepare PMA application — Compile a far more extensive package than a 510(k):

   • Complete device description and principle of operation
   • Manufacturing information (process, controls, specifications)
   • Non-clinical laboratory studies (bench testing, biocompatibility, animal studies)
   • Clinical investigations (full clinical study report with patient-level data)
   • Proposed labeling (professional and patient labeling, IFU)
   • Summary of safety and effectiveness data (SSED)
   • Bibliography of all published literature relevant to the device
   • Environmental assessment or claim of categorical exclusion

4. Submit PMA and pay user fee — $579,272 standard / $144,818 small business for FY2026.

5. Administrative and filing review (45 days) — The FDA determines whether the PMA is sufficiently complete to file for review. If not, the FDA issues a Refuse to File (RTF) letter.

6. Substantive review (180 FDA days from filing) — The FDA review division conducts an in-depth technical review. Key milestones during this period:

   • Day 100 meeting — A milestone meeting between the FDA and the applicant to discuss the review status, outstanding questions, and any deficiencies. This meeting is now formalized under MDUFA V.
   • Additional Information (AI) requests — Major deficiency letters that stop the review clock. Responding to AI requests can take weeks to months.
   • Advisory panel meeting (if applicable) — For first-of-a-kind devices, the FDA convenes the relevant advisory committee for a public hearing and vote on approvability. The panel's recommendation is advisory — the FDA makes the final decision.

7. Pre-approval inspection — The FDA inspects the manufacturing facility to verify compliance with 21 CFR Part 820 (Quality System Regulation, transitioning to QMSR). The FDA will not approve a PMA until the inspection is satisfactorily completed.

8. Decision — The FDA issues one of four outcomes:

   • Approval — The device is approved. You receive an approval order with any conditions of approval (e.g., post-approval studies, labeling requirements).
   • Approvable — The FDA will approve the device if you address specific minor conditions within a specified timeframe.
   • Not Approvable — The FDA identifies significant deficiencies that preclude approval. You may request a hearing or withdraw the application.
   • Withdrawal — You withdraw the application voluntarily.

Submission Content Comparison

Understanding exactly what goes into each submission helps you plan your preparation timeline and resource allocation.

Content Element	510(k)	PMA
Cover letter	Yes	Yes
Table of contents	Yes	Yes
Administrative information	Applicant info, contact, establishment registration number	Applicant info, contact, establishment registration number
Device description	Description, principles of operation, photographs, engineering drawings	Comprehensive description, principles of operation, complete specifications, photographs, engineering drawings
Intended use / indications for use	Indications for Use Statement (FDA Form 3881)	Complete intended use statement with detailed indications, contraindications, warnings, precautions
Predicate comparison	Side-by-side comparison table with predicate(s)	Not applicable (no predicate)
Substantial equivalence discussion	Detailed SE argument	Not applicable
Manufacturing information	Not typically required	Required — manufacturing process, controls, specifications, environmental controls, quality system procedures
Non-clinical testing	Performance data comparing to predicate	Complete bench testing package including all characterization data
Biocompatibility	ISO 10993 evaluation (if patient contact)	ISO 10993 evaluation plus any animal study data
Clinical data	Optional (if required, clinical study report or literature review)	Required — full clinical study report with patient-level data
Software documentation	Software level of concern, documentation per FDA guidance	Full software documentation per IEC 62304 and FDA guidance
Sterilization data	Validation summary (if sterile)	Full validation package (if sterile)
Labeling	Draft labeling (professional labeling, IFU)	Complete proposed labeling (professional labeling, patient labeling, IFU)
Summary / SSED	510(k) summary or 510(k) statement	Summary of Safety and Effectiveness Data (SSED) — a comprehensive public document
Environmental assessment	Not required	Required (or claim of categorical exclusion)
Bibliography	Not typically required	Complete bibliography of all relevant literature
Typical page count	200-2,000 pages	5,000-50,000+ pages

Timeline Comparison

Milestone	510(k)	PMA
Pre-Submission feedback	~75 days from Q-Sub receipt	~75 days from Q-Sub receipt
Clinical trial (if required)	6-18 months (rare)	1-5+ years
Submission preparation	2-6 months	6-18 months
Acceptance/filing review	15 days	45 days
Substantive review (FDA days)	90 days (MDUFA V goal)	180 days (statutory)
Total time to decision (calendar)	~130 days (median)	~285 days (MDUFA V goal, excluding clinical trial)
Total program duration (typical)	6-18 months	3-7+ years

Common Deficiencies and FDA Feedback Patterns

Understanding why the FDA pushes back on submissions can help you avoid the most common pitfalls.

Common 510(k) deficiencies (AI request triggers):

• Inadequate predicate justification — the predicate has a different intended use or the technological differences are not adequately addressed
• Missing or incomplete performance testing — bench data does not cover all relevant performance characteristics
• Insufficient biocompatibility evaluation — material characterization is incomplete or the biological evaluation plan does not follow ISO 10993-1
• Software documentation gaps — missing hazard analysis, incomplete software requirements specification, or inadequate cybersecurity documentation
• Labeling deficiencies — inconsistencies between the intended use statement and the labeling content

Common PMA deficiencies (major deficiency letter triggers):

• Clinical study design inadequacies — insufficient enrollment, inappropriate control group, endpoints that do not align with intended use
• Incomplete or inconsistent clinical data — missing follow-up data, protocol deviations not adequately addressed, statistical analysis plan changes not justified
• Manufacturing information gaps — process validation incomplete, specifications not adequately justified, supplier controls not documented
• Labeling that does not reflect clinical study population — indications broader than the studied population, missing contraindications identified in the study

Practical tip: The 510(k) RTA (Refuse to Accept) rate has historically been 15-25%, meaning one in four to six submissions is returned before review even begins. The most effective way to avoid an RTA is to use the FDA's RTA checklist (available for each submission type) as a final quality check before submitting. For PMAs, the Refuse to File rate is lower (~5-10%) but the consequences are more severe given the time and cost already invested.

Practical tip: The 180-day statutory clock for PMA review pauses every time the FDA issues an AI request. The shared MDUFA V total-time-to-decision goal of 285 calendar days reflects expected hold times, but complex applications with multiple AI rounds can take 18-24+ months from submission to approval.

Cost Comparison: The Full Picture

User fees are only the tip of the cost iceberg. The total cost to reach market through each pathway differs by one to two orders of magnitude.

User Fees (FY2026)

Fee Type	510(k)	PMA	De Novo
Standard	$26,067	$579,272	$173,782
Small business (≤ $100M gross receipts)	$6,517	$144,818	$43,446
First PMA/De Novo waiver (≤ $30M gross receipts)	N/A	Waived	Waived
Annual establishment registration	$11,423	$11,423	$11,423

Total Cost to Market (Typical Ranges)

Cost Category	510(k)	PMA
User fee	$6.5K-$26K	$145K-$579K
Regulatory consulting	$30K-$150K	$200K-$1M+
Bench / non-clinical testing	$20K-$250K	$200K-$2M
Biocompatibility testing	$10K-$150K	$50K-$500K
Clinical trial	$0-$500K (if needed)	$5M-$50M+
Software documentation (if SaMD)	$20K-$100K	$50K-$300K
Manufacturing / QMS setup	$50K-$300K	$200K-$2M
Pre-approval inspection readiness	N/A	$50K-$200K
Total estimated range	$50K-$500K	$5M-$75M+

The median total cost to bring a device to market through the PMA pathway has been estimated at approximately $94 million when full development costs are included, compared to approximately $31 million for 510(k) devices. However, these figures include non-regulatory costs (R&D, manufacturing scale-up, reimbursement) that vary enormously by device type.

MDUFA V User Fee Context

Under MDUFA V (FY2023-FY2027), user fees are adjusted annually for inflation. The base fee for a premarket application (PMA, PDP, or BLA) in FY2026 is $579,272. All other fees are set as percentages of this base:

• 510(k) = ~4.5% of PMA base fee → $26,067
• De Novo = ~30% of PMA base fee → $173,782
• PMA supplement (panel-track) = ~75% of PMA base fee → ~$434,454
• PMA supplement (180-day) = ~25% of PMA base fee → ~$144,818
• PMA supplement (real-time) = ~4% of PMA base fee → ~$23,171
• Annual establishment registration = $11,423

Small businesses with gross receipts or sales under $100 million qualify for a 75% reduction in submission fees. Businesses with gross receipts under $30 million may qualify for a complete waiver of the fee for their first PMA, PDP, or BLA.

Practical tip: For startups, the PMA pathway has enormous implications for fundraising. A PMA-track device typically requires $10M-$50M+ in venture funding before generating any revenue. Factor this into your business plan and investor communications from day one. If your device can qualify for De Novo classification (Class I or II), it may dramatically change your capital requirements.

Practical tip: The PMA user fee is due at submission — not at approval. If your PMA is found Not Approvable or you withdraw the application, the fee is not refunded. Budget accordingly and ensure your submission is as complete as possible before filing.

Post-Market Obligations: What Happens After Authorization

510(k) Post-Market Requirements

Devices cleared through 510(k) are subject to the standard general controls that apply to all medical devices:

• Establishment registration and device listing — Annual registration and listing with the FDA (21 CFR Part 807)
• Quality System Regulation — Compliance with 21 CFR Part 820 (transitioning to QMSR aligning with ISO 13485), including design controls
• Medical Device Reporting (MDR) — Report deaths, serious injuries, and malfunctions to the FDA within the required timeframes (21 CFR Part 803)
• Labeling — Comply with labeling requirements under 21 CFR Part 801
• Corrections and removals — Report recalls and corrections to the FDA (21 CFR Part 806)
• Post-market surveillance — Not routinely required, but the FDA can order post-market surveillance under Section 522 for any device if it determines there is a concern

510(k)-cleared devices do not have annual reporting requirements to the FDA. There is no obligation to submit periodic safety updates unless ordered by the FDA.

PMA Post-Market Requirements

PMA-approved devices carry all the general controls obligations listed above, plus significant additional requirements:

• PMA annual report (21 CFR 814.84) — Within 60 days of the anniversary of PMA approval, you must submit an annual report that includes:

  • All device modifications made under any PMA supplement or 30-day notice
  • All quality system changes affecting the device
  • Bibliography of new clinical investigations, scientific articles, and unpublished reports
  • Summary of any new adverse events and complaints
  • Status of any post-approval studies
  • Distribution data (number of units distributed)
  • A brief summary of any device failures or replacements

• Post-approval studies — The FDA commonly requires post-approval studies (PAS) as a condition of PMA approval. These are long-term prospective studies that continue to monitor safety and effectiveness in the post-market environment, often enrolling thousands of patients with follow-up of 5-10 years.

• Conditions of approval — The FDA may impose specific conditions on PMA approval, such as restricted distribution, additional labeling requirements, mandatory training programs for healthcare providers, or patient tracking requirements.

• Post-market surveillance orders — The FDA is more likely to issue Section 522 orders for PMA devices, requiring manufacturers to conduct active surveillance studies.

Post-Market Comparison Table

Post-Market Obligation	510(k)	PMA
Establishment registration	Annual	Annual
MDR (adverse event reporting)	Required	Required
QSR/QMSR compliance	Required	Required
Annual report to FDA	Not required	Required (21 CFR 814.84)
Post-approval study	Not applicable	Often required as condition of approval
Post-market surveillance (Section 522)	Possible but rare	More common
Ongoing clinical data collection	Not typically required	Often required

Labeling and Marketing Claim Differences

The type of FDA authorization you hold directly affects what you can say about your device in marketing materials, on your website, and in communications with healthcare providers and patients.

510(k)-Cleared Devices

• You may state your device is "FDA cleared" or "510(k) cleared" — never "FDA approved"
• Your marketing claims must stay within the scope of your cleared intended use / indications for use
• You may reference your 510(k) clearance number (e.g., K241234)
• You may not make comparative superiority claims against the predicate unless supported by evidence — your clearance is based on equivalence, not superiority
• Promotional materials are subject to FDA enforcement action if they contain claims beyond the cleared labeling

PMA-Approved Devices

• You may state your device is "FDA approved"
• Your marketing claims must stay within the conditions of approval and the approved labeling
• The Summary of Safety and Effectiveness Data (SSED) is a public document — competitors, clinicians, and patients can read your clinical results, adverse event rates, and any conditions of approval
• Promotional materials are subject to the same FDA enforcement standards, but PMA-approved devices generally have richer clinical data to support marketing claims
• Off-label promotion restrictions apply equally to both pathways

Practical tip: Your reimbursement team should be involved in labeling and claims strategy from the beginning. CMS and private payers make coverage decisions based on the FDA-authorized intended use and the clinical evidence supporting it. A narrow or ambiguously worded intended use statement can limit reimbursement even if the device is technically cleared or approved.

Change Management: Modifications After Authorization

How you manage changes to your device after initial authorization is one of the most consequential operational differences between the two pathways.

510(k) Change Management

When you modify a 510(k)-cleared device, you assess whether the change is significant enough to require a new 510(k) submission. The FDA's guidance document "Deciding When to Submit a 510(k) for a Change to an Existing Device" (2017) provides the decision framework.

• Letter-to-file — If the modification does not significantly affect safety or effectiveness, you document the rationale in a letter-to-file within your quality system. No FDA submission required.
• New 510(k) — If the modification is significant — meaning it could affect safety or effectiveness, changes the intended use, or involves a new technology — you submit a new 510(k). This can be a Traditional, Special, or Abbreviated 510(k) depending on the nature of the change.

The decision of "significant" vs. "not significant" is the manufacturer's responsibility. The FDA can audit your letter-to-file decisions during inspections and challenge them retroactively.

PMA Change Management

PMA-approved devices have a far more structured and burdensome change management process. The type of PMA supplement required depends on the significance of the change:

Supplement Type	Description	Typical Use	FDA Review Goal
Panel-track supplement	Significant change in design, performance, or new indication requiring clinical data	New indication for use, major design change with clinical implications	180 FDA days; may go to advisory panel
180-day supplement	Significant change not requiring panel-track review	Component or material change, manufacturing process change, new sterilization method	180 FDA days
Real-time supplement	Minor change reviewed interactively with FDA	Minor software update, minor labeling change	~30 days (interactive review meeting)
Special PMA supplement — manufacturing site change	Change in manufacturing site	Moving production to a new facility	30 FDA days (review goal)
30-day notice (21 CFR 814.39(e))	Minor change that may be implemented 30 days after FDA receipt unless FDA objects	Minor labeling changes, editorial changes to manufacturing documentation	30 days (if FDA does not object, change can be implemented)
Annual report change (21 CFR 814.39(d))	Minor change documented in next annual report	Editorial changes, changes in supplier that do not affect device	N/A (reported in next annual report)

Practical tip: The practical implication of PMA change management is that even relatively minor modifications — such as changing a component supplier, updating software, or modifying a manufacturing process step — often require an FDA supplement with a review period of 30 to 180 days before you can implement the change. This slows product iteration significantly compared to 510(k) devices, where the same change might be documented in a letter-to-file and implemented immediately.

The De Novo Pathway: The Third Option You Must Consider

The De Novo classification request under Section 513(f)(2) of the FD&C Act is not merely an "alternative" — for many novel devices, it is the strategically correct pathway. If your device is truly novel (no predicate exists) but its risk profile is low to moderate, De Novo avoids the cost and timeline of PMA while establishing your device as the predicate for future 510(k) submissions by competitors.

When to Use De Novo

• Your device has no legally marketed predicate device
• Your device is low-to-moderate risk (appropriate for Class I or Class II classification)
• General controls alone (Class I) or general controls plus special controls (Class II) are sufficient to provide reasonable assurance of safety and effectiveness
• You want to create a new classification regulation and product code for your device type

De Novo Process

1. Direct submission — Since 2021, you can submit a De Novo request directly without first receiving an NSE determination on a 510(k). This "direct to De Novo" route saves time.
2. Acceptance review — The FDA has 15 days to accept or reject the submission for substantive review.
3. Substantive review — The FDA evaluates the proposed classification, proposed special controls, and supporting data. The MDUFA V goal is 150 FDA days for 70% of submissions.
4. Decision — If granted, the FDA creates a new classification regulation, assigns a product code, and specifies any special controls. Your device becomes the predicate for future 510(k) submissions.

De Novo vs. PMA for Novel Devices

Factor	De Novo	PMA
Risk level	Low to moderate	High
Creates new classification?	Yes — new product code, regulation number	No — device remains Class III
Future devices can use 510(k)?	Yes — your device becomes the predicate	No — future devices must also go through PMA
Typical clinical data burden	Moderate (often less extensive than PMA)	Extensive (pivotal clinical trial)
Cost	$200K-$3M+	$5M-$75M+
Review timeline	~250 calendar days (median)	~12-18+ months
Post-market annual report?	No	Yes

Recent Regulatory Developments Affecting Both Pathways

The regulatory landscape is not static. Several recent developments have meaningful implications for pathway strategy.

eSTAR Mandate Expansion

As of October 1, 2023, all 510(k) submissions must be submitted using the electronic Submission Template and Resource (eSTAR) format. As of October 1, 2025, De Novo classification requests must also use eSTAR. PMA applications are not currently required to use eSTAR but must be submitted as electronic copies (eCopy). The FDA has proposed expanding the eSTAR requirement to Q-Submissions as well.

The eSTAR format standardizes submission structure and has reduced RTA rates for 510(k) submissions by ensuring all required sections are included. If you are preparing a 510(k) or De Novo, download the latest eSTAR template from the FDA website and familiarize your team with its structure before beginning submission preparation.

QSR to QMSR Transition

The FDA finalized the Quality Management System Regulation (QMSR) in January 2025, replacing the legacy Quality System Regulation (QSR) at 21 CFR Part 820. The QMSR incorporates ISO 13485:2016 by reference, harmonizing the US quality system requirements with the international standard. The transition period extends through February 2026.

This transition affects both pathways equally — all device manufacturers must comply with the QMSR regardless of whether their device is 510(k)-cleared or PMA-approved. However, PMA manufacturers face the additional pressure of ensuring their QMS is QMSR-compliant before their next pre-approval inspection or surveillance inspection.

FDA's Predicate Modernization Efforts

The FDA has continued its efforts to strengthen the 510(k) program by limiting the use of outdated predicates. In recent years, the agency has eliminated over 1,750 devices as predicates and has encouraged manufacturers to use the most recent predicates available rather than relying on decades-old clearances. This trend may narrow the predicate landscape for some device types, potentially pushing more devices toward De Novo or PMA.

MDUFA V Performance Goals: What the FDA Has Committed To

The Medical Device User Fee Amendments V (MDUFA V), signed into law in September 2022 as part of the FDA User Fee Reauthorization Act (FUFRA), establishes the performance goals that govern FDA review times for FY2023-FY2027. Understanding these commitments helps you set realistic timeline expectations.

Review Time Goals by Submission Type

Submission Type	FDA Day Goal	Percentage Target	Calendar Day Goal (Total Time to Decision)
510(k)	90 FDA days	95% of decisions within goal	~128 days (FY2023) decreasing to ~112 days (FY2025+)
Original PMA / Panel-Track Supplement	180 FDA days (statutory)	N/A (statutory requirement)	285 calendar days (shared FDA-industry goal, FY2025-2027)
180-Day PMA Supplement	180 FDA days	90% of decisions within goal	N/A
Real-Time PMA Supplement	~30 days (interactive review)	N/A	N/A
De Novo	150 FDA days	70% of decisions within goal	~250 calendar days (including hold times)
IDE	30 days (approval/disapproval)	N/A (statutory)	N/A

Key MDUFA V Innovations

• Shared Outcome Total Time to Decision (TTTD) — For the first time, MDUFA V introduced shared accountability for total calendar time. Both the FDA and industry share responsibility for the 285-day TTTD goal for original PMAs, recognizing that applicant response times to AI requests contribute significantly to total review duration.
• Quarterly performance reports — The FDA publishes quarterly MDUFA V performance reports tracking actual review times against goals. These reports are publicly available and provide transparency into whether the FDA is meeting its commitments.
• Pre-Submission response goals — MDUFA V established formal goals for Pre-Submission feedback timing, which had previously been informal.

Practical tip: When planning your regulatory timeline, use the MDUFA V calendar-day goals as your baseline, then add buffer for AI requests and response preparation. For 510(k), plan for 4-6 months from submission to decision. For PMA, plan for 10-15 months from submission to decision (excluding clinical trial time). Check the latest quarterly MDUFA performance report to see whether the FDA is currently meeting its goals for your submission type.

Pre-Submission (Q-Sub) Strategy for Both Pathways

The FDA's Q-Submission program is the single most valuable tool available to manufacturers for both pathways. A well-executed Pre-Submission can prevent months of wasted effort by aligning your regulatory strategy with the FDA's expectations before you invest in testing and clinical trials.

Q-Sub Types Relevant to PMA and 510(k)

Q-Sub Type	Purpose	Applicable To
Pre-Submission (Pre-Sub)	Seek FDA feedback on regulatory pathway, testing strategy, clinical study design, predicate selection	510(k), PMA, De Novo, IDE
Study Risk Determination	Obtain FDA determination on whether a planned clinical study is significant risk, non-significant risk, or exempt	IDE, PMA, 510(k) (if clinical data planned)
Submission Issue Request (SIR)	Resolve specific technical or regulatory issues during active FDA review of a pending submission	510(k), PMA, De Novo
PMA Day 100 Meeting	Mid-review meeting to discuss deficiencies and review status	PMA only

Pre-Sub Best Practices

• Submit specific, focused questions — not open-ended requests for the FDA to design your regulatory strategy
• Include a detailed device description, proposed intended use, proposed predicate (for 510(k)), proposed testing plan, and your regulatory rationale
• Request a meeting (teleconference or in-person) in addition to written feedback — the interactive discussion is often more valuable than the written response
• Allow 75 days from FDA receipt to the meeting
• For PMA-track devices, plan for multiple Pre-Submissions: one early (pathway and study design), one mid-development (protocol finalization), and one pre-submission (final content review)

Practical tip: The FDA updated its Q-Submission guidance in May 2025, formalizing the PMA Day 100 meeting and adding new provisions for Submission Issue Requests. Review the current guidance before submitting your Q-Sub.

Third-Party Review for 510(k) and Advisory Panel Review for PMA

510(k) Third-Party Review Program (3P510k)

The 510(k) Third Party Review Program, authorized under Section 523 of the FD&C Act, allows manufacturers of certain low-to-moderate risk devices to submit their 510(k) to an FDA-recognized third-party review organization (3P510k RO) instead of directly to the FDA.

How it works:

• You submit your 510(k) to a recognized third-party organization
• The third party conducts the substantive review and issues a recommendation to the FDA
• The FDA makes the final clearance decision, but the third-party review offloads much of the review workload
• Target review time is faster than direct FDA review for eligible device types

Eligibility: Not all device types qualify. The program is limited to devices that the FDA has determined are appropriate for third-party review — generally well-understood, lower-risk Class II devices. High-risk devices, novel technologies, and devices with significant clinical data requirements are excluded.

2025 guidance update: The FDA finalized guidance on the 3P510k program in early 2025, expanding the program's scope and clarifying procedures for third-party organizations, including provisions for emergency use authorization (EUA) reviews.

PMA Advisory Panel Review

For PMA applications, the FDA may convene an advisory committee (panel) to review the application at a public meeting and provide a recommendation on approvability.

When panels are convened:

• First-of-a-kind devices for a device type typically go to panel
• The FDA has discretion to refer any PMA to an advisory panel if it determines the application raises issues best addressed through panel review
• Once the FDA has established sufficient experience with a device type, subsequent PMAs for similar devices are typically not referred to panels

Panel meeting process:

• The FDA assigns a primary reviewer from the advisory committee who prepares a clinical evaluation
• The meeting is public — sponsors present their data, the FDA presents its review, and public comments are heard
• The panel votes on specific questions (e.g., "Has the applicant demonstrated a reasonable assurance of safety?", "Has the applicant demonstrated a reasonable assurance of effectiveness?", "Do the benefits outweigh the risks?")
• The panel's vote is advisory — the FDA is not bound by it, though it is rare for the FDA to deviate significantly from a unanimous panel recommendation

Strategic implication: A panel meeting adds 2-4 months to the PMA timeline. It is also a public event — your clinical data, study results, and any device limitations will be discussed openly. Preparation for a panel meeting is a significant effort, often involving dry runs with mock panels and extensive slide preparation.

Breakthrough Device Designation: Impact on Both Pathways

The Breakthrough Devices Program (Section 515B of the FD&C Act) provides expedited review for devices that offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The designation is available for devices pursuing PMA, 510(k), or De Novo pathways.

Eligibility Criteria

Your device must:

1. Provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating human disease or condition, AND
2. Meet at least one of the following: represents breakthrough technology, no approved or cleared alternatives exist, offers significant advantages over existing alternatives, or device availability is in the best interest of patients

Benefits of Breakthrough Designation

Benefit	Impact
Dedicated FDA team	Assigned review team for ongoing communication
Sprint discussions	Rapid-turnaround meetings to resolve issues quickly
Priority review	Expedited review of the premarket submission
Flexible clinical study design	FDA may accept alternative study designs, surrogate endpoints, or smaller studies
Data development plan	Collaborative agreement on pre- and post-market evidence needs
Post-market data in lieu of pre-market data	Possibility to shift some evidence burden to post-market
CMS TCET pathway	Eligible for Medicare Transitional Coverage for Emerging Technologies — coverage within ~6 months vs. typical 5-year process

Program Statistics (as of December 2025)

• 1,246 total Breakthrough Device designations granted (CDRH and CBER combined)
• 185 total marketing authorizations for Breakthrough-designated devices
• Average review time savings estimated at approximately 75 days (based on FOIA data analysis)

Practical tip: Breakthrough designation does not change your regulatory pathway — you still go through the full PMA, 510(k), or De Novo process. However, the more interactive review process, flexible clinical study design, and priority review can meaningfully accelerate your timeline. Apply early in development, before your pivotal study begins, to maximize the benefit of FDA engagement on study design.

International Implications

US FDA authorization — whether 510(k) clearance or PMA approval — carries different weight in different international markets. Your US pathway choice has downstream implications for global regulatory strategy.

Where US Authorization Is Recognized

Market	Recognition of US Authorization	Notes
United Kingdom (MHRA)	Partial — MHRA's international recognition framework accepts certain FDA-authorized devices (510(k) and PMA) depending on risk class	Class IIa and some IIb devices with FDA authorization may qualify for recognition; Class III devices may still require independent assessment
European Union (MDR/IVDR)	No direct recognition — EU requires independent CE marking	EU MDR uses a fundamentally different classification and conformity assessment paradigm; US clinical data is accepted but the regulatory file is independent
Japan (PMDA)	No direct recognition — independent shonin (approval) or todokede (notification) required	Japan accepts US clinical data and FDA-cleared manufacturing information, which can streamline the Japanese submission
Canada (Health Canada)	No direct recognition, but significant data overlap	Health Canada accepts FDA review data as supporting evidence; MDSAP audit covers both FDA QSR and Health Canada requirements
Australia (TGA)	No direct recognition, but accepts comparable evidence	TGA accepts foreign regulatory decisions as supporting information for conformity assessment
Brazil (ANVISA)	Partial — ANVISA may accept FDA clearance/approval as supporting evidence for certain risk classes	GMP certificate from FDA inspection may be accepted in lieu of separate ANVISA GMP audit

Strategic Considerations for Global Market Access

A PMA approval generally carries more international credibility than a 510(k) clearance because PMA involves an independent FDA assessment of safety and effectiveness based on clinical evidence. Some international regulators view 510(k) clearance as less rigorous because it relies on substantial equivalence rather than de novo evidence of safety and effectiveness. This can matter when you are negotiating with international notified bodies, regulatory authorities, or reimbursement agencies.

Clinical data portability: One of the most important strategic considerations is whether the clinical data you generate for one market can be reused in another. Clinical data generated for a PMA pivotal trial is generally accepted by international regulators (EU, Japan, Canada, Australia) as supporting evidence, provided the study was conducted under Good Clinical Practice (GCP). The FDA explicitly accepts foreign clinical data for PMA applications, and most international regulators reciprocate. This means your PMA clinical trial can serve double or triple duty — supporting FDA approval, EU MDR conformity assessment, and Japanese PMDA shonin simultaneously.

For 510(k) devices, the clinical data question is simpler because most 510(k) devices do not require clinical trials. However, the EU MDR does not recognize the concept of substantial equivalence in the way the FDA does — the EU has its own equivalence criteria under MDR Article 61(5), which are more restrictive. A device cleared through 510(k) in the US may require clinical investigation data for CE marking in Europe, even if no clinical data was needed for the US market.

MDSAP and multi-market QMS audits: The Medical Device Single Audit Program (MDSAP) allows a single audit to satisfy the QMS requirements of the US (FDA), Canada (Health Canada), Brazil (ANVISA), Japan (PMDA/MHLW), and Australia (TGA). For manufacturers pursuing both 510(k)/PMA in the US and market authorization in other MDSAP countries, an MDSAP audit can reduce the total audit burden and provide a unified quality system assessment.

FDA Inspection and Compliance: How Enforcement Differs

Both 510(k) and PMA manufacturers are subject to FDA inspections, but the timing, scope, and consequences differ.

Pre-Market Inspections

510(k) devices: No pre-clearance inspection is required. The FDA clears your device based on the submission alone. However, you are expected to be in compliance with 21 CFR Part 820 (QSR/QMSR) from the moment you begin commercial distribution. The FDA may inspect your facility at any time after clearance, and if it finds significant quality system violations, it can issue Form 483 observations, Warning Letters, or even withdraw your clearance.

PMA devices: A pre-approval inspection (PAI) is mandatory. The FDA will not issue a PMA approval order until it has inspected your manufacturing facility and confirmed compliance with the QSR/QMSR. The PAI typically occurs during the latter portion of the PMA review period (after the Day 100 meeting). The inspection covers:

• Design controls (21 CFR 820.30) — The inspector reviews your entire design history file (DHF) for the PMA device
• Production and process controls — Manufacturing process validation, environmental monitoring, in-process testing
• CAPA system — Review of your corrective and preventive action procedures and recent CAPA records
• Complaint handling and MDR — Review of complaint files and adverse event reporting
• Management responsibility — Review of management review records and quality policy

Post-Market Inspections

Both 510(k) and PMA manufacturers are subject to routine biennial inspections (every two years for Class II and Class III manufacturers). However, PMA manufacturers face additional scrutiny:

• More frequent inspections — PMA manufacturers are inspected more frequently than 510(k)-only manufacturers in practice
• Post-approval study monitoring — The FDA verifies that any required post-approval studies are being conducted according to the approved protocol
• Annual report review — FDA may use your annual report as the basis for inspection focus areas
• Supplement compliance — The FDA verifies that you have filed appropriate PMA supplements for device modifications and have not implemented changes without authorization

Enforcement Actions

The consequences of non-compliance are generally more severe for PMA devices because the FDA has more granular control over the approval:

• For 510(k) devices, the FDA's primary enforcement tools are Warning Letters, consent decrees, injunctions, and seizure
• For PMA devices, the FDA has the additional authority to withdraw PMA approval — effectively removing the device from the market. This is a powerful enforcement mechanism that does not exist for 510(k)-cleared devices (which have no "approval" to withdraw)

Practical tip: If you are pursuing a PMA, begin your pre-approval inspection readiness program at least 6-12 months before your anticipated PMA submission date. The PAI is a pass/fail gate — if the FDA finds significant deficiencies, your approval will be delayed until the deficiencies are corrected and verified.

Decision Framework: How to Choose the Right Pathway

Use this structured decision tree to determine the appropriate regulatory pathway for your device.

Step 1: Determine Device Classification

• Search the FDA Product Classification Database for your device type
• If your device matches an existing product code, the classification panel and regulatory requirements are defined
• If no existing product code exists, your device is automatically Class III under Section 513(f)(1) — but De Novo may be appropriate

Step 2: Assess Predicate Availability

• Predicate exists and your device is substantially equivalent → 510(k)
• No predicate exists and your device is low-to-moderate risk → De Novo
• No predicate exists and your device is high risk → PMA
• Predicate exists but your device raises new questions of safety/effectiveness that cannot be resolved through bench testing → Consider whether 510(k) with clinical data is viable, or whether De Novo or PMA is more appropriate

Step 3: Evaluate Risk and Regulatory Class

• Class I (non-exempt) → 510(k)
• Class II → 510(k) (most common) or De Novo (if no predicate)
• Class III with existing PMA regulation → PMA
• Class III pre-amendment (no PMA regulation called) → 510(k) may be possible (rare)

Step 4: Consider Business and Strategic Factors

• Timeline constraints — If speed to market is critical and a predicate exists, 510(k) is the fastest route
• Funding constraints — If capital is limited, the $5M-$75M+ PMA cost may not be feasible; explore De Novo if possible
• Competitive landscape — A PMA creates a higher barrier to entry for competitors (they must also go through PMA); a De Novo creates a predicate that competitors can use for 510(k)
• Reimbursement — PMA approval with clinical trial data may support stronger reimbursement arguments; however, Breakthrough-designated devices can access CMS TCET regardless of pathway
• International strategy — PMA approval may carry more weight in international markets

Step 5: Account for Combination Product and Special Device Considerations

Some devices do not fit neatly into the standard pathway framework:

• Combination products (device + drug or device + biologic) — The pathway depends on the primary mode of action (PMOA). If the device is the PMOA, the device center (CDRH) leads the review, and the pathway is typically PMA or 510(k) depending on classification. If the drug or biologic is the PMOA, the drug center (CDER) or biologic center (CBER) leads, and the device component is reviewed as part of an NDA or BLA. Request a Request for Designation (RFD) from the Office of Combination Products if the PMOA is unclear.
• In vitro diagnostics (IVDs) — Most IVDs follow the same pathway framework, but IVDs have specific classification rules and may be reviewed by CDRH or CBER depending on the analyte. High-risk IVDs (e.g., HIV screening tests, companion diagnostics) typically require PMA. Moderate-risk IVDs typically require 510(k). Novel IVDs with no predicate may use De Novo.
• Custom devices — Devices made on an individual basis to a physician's prescription may qualify for the custom device exemption under Section 520(b), which allows limited production without any premarket submission. Strict criteria apply.
• Humanitarian Use Devices (HUDs) — For devices intended for conditions affecting fewer than 8,000 patients per year in the US, the Humanitarian Device Exemption (HDE) pathway under Section 520(m) may be appropriate. HDE requires safety evidence but not effectiveness evidence.

Decision Summary Table

Your Situation	Recommended Pathway	Key Consideration
Class II device with a valid predicate	510(k)	Ensure SE can be demonstrated
Class II device, modification to your own device	Special 510(k)	30-day review if eligible
Class III device with existing PMA regulation	PMA	Budget for clinical trial
Novel device, no predicate, low-moderate risk	De Novo	Creates new classification
Novel device, no predicate, high risk	PMA	Full clinical evidence required
Class III pre-amendment, no PMA called	510(k) (rare)	Verify no call-for-PMA order
Condition affecting <8,000 patients/year	HDE	Safety only (no efficacy required)
Combination product, device is PMOA	PMA or 510(k) (per classification)	CDRH leads review
Novel IVD, moderate risk	De Novo or 510(k)	Check for predicate availability

Real-World Decision Scenarios

Scenario 1: Novel AI-Powered Retinal Screening Software

Situation: A startup has developed an AI algorithm that autonomously screens retinal images for diabetic retinopathy, producing a positive or negative result without physician interpretation. No predicate exists for an autonomous AI diagnostic device in ophthalmology.

Analysis: No predicate device exists, so 510(k) is not an option. The device is moderate risk — it is software, non-invasive, and the clinical condition is well-understood. PMA would be unnecessarily burdensome for a software device.

Correct pathway: De Novo — Demonstrate reasonable assurance of safety and effectiveness through a clinical study comparing the algorithm's performance to expert graders. Propose Class II classification with special controls specifying clinical performance criteria, labeling requirements, and software validation standards. This is exactly the path IDx-DR followed to become the first FDA-authorized autonomous AI diagnostic device.

Scenario 2: New Coronary Drug-Eluting Stent

Situation: A large medical device company has developed a next-generation drug-eluting coronary stent with a novel polymer coating and a new antiproliferative drug.

Analysis: Drug-eluting coronary stents are Class III devices regulated under an existing PMA classification. No 510(k) predicate pathway exists. The device sustains life and is implanted in the coronary vasculature — this is as high-risk as it gets.

Correct pathway: PMA — Conduct a pivotal IDE clinical trial (likely an RCT against the current standard-of-care stent) enrolling 1,000+ patients with 12-month primary endpoint and 5-year follow-up. Expect advisory panel review. Plan for a post-approval study. Budget $30M-$75M+ for the clinical and regulatory program.

Scenario 3: Modified Pulse Oximeter with Improved Sensor

Situation: A company already has a 510(k)-cleared pulse oximeter and wants to introduce a new sensor design that improves accuracy in patients with dark skin tones. The intended use is unchanged. The form factor is unchanged. The improvement is in the optical sensor configuration.

Analysis: A predicate exists (the company's own prior clearance). The intended use is unchanged. The modification improves performance but does not raise new safety questions. The change was evaluated through the company's design controls.

Correct pathway: Special 510(k) — Reference the company's own prior clearance as the predicate. Document the design control process, risk analysis, and verification/validation activities. Target 30-day FDA review.

Scenario 4: Novel Implantable Neurostimulator for Treatment-Resistant Depression

Situation: A medical device company has developed a new implantable neurostimulator that targets a novel brain region for treatment-resistant depression. There is no FDA-authorized neurostimulation device for depression targeting this specific brain region.

Analysis: Implantable neurostimulators are Class III devices. The novel target brain region means no predicate exists. The device is implanted, sustains therapeutic function, and involves significant surgical risk. This is a high-risk, first-of-a-kind device.

Correct pathway: PMA — File an IDE for a pivotal clinical trial. Given the novel mechanism and psychiatric indication, expect FDA to require an RCT with sham control, enrollment of 200+ patients, and minimum 12-month follow-up. Advisory panel review is virtually certain. Breakthrough Device Designation is worth pursuing given the unmet need in treatment-resistant depression.

Scenario 5: Digital Therapeutic App for Insomnia

Situation: A digital health company has developed a mobile app that delivers cognitive behavioral therapy for insomnia (CBT-I) as a prescription digital therapeutic. No predicate device exists, and the software does not control any hardware device.

Analysis: This is a software-only device (SaMD) with no predicate. The device is low-to-moderate risk — it delivers behavioral therapy content and does not perform invasive procedures or make autonomous diagnostic decisions. A 510(k) is not possible without a predicate. PMA would be disproportionate to the risk.

Correct pathway: De Novo — Propose Class II classification with special controls addressing software validation, clinical evidence of therapeutic effectiveness, cybersecurity, and usability. A clinical study demonstrating improvement in sleep outcomes will be needed. This mirrors the approach taken by Pear Therapeutics for Somryst (now authorized as a Class II device).

Scenario 6: Updated Surgical Robot with New Instrument Arm

Situation: A company with an existing PMA-approved surgical robot wants to add a new instrument arm that expands the system's capability to a different surgical specialty.

Analysis: The base system is PMA-approved. Adding a new instrument arm that enables use in a new surgical specialty is a significant change in performance and introduces a new indication for use. Clinical data for the new specialty will likely be needed.

Correct pathway: Panel-track PMA supplement — This is a significant change to an approved PMA device involving new indications and likely requiring clinical data. The FDA may refer this to an advisory panel. A 180-day supplement would be insufficient given the scope of the change.

Scenario 7: Rapid Diagnostic Test for a Novel Infectious Disease Biomarker

Situation: A diagnostics company has developed a rapid point-of-care test for a newly identified biomarker associated with early-stage sepsis. No existing test detects this biomarker.

Analysis: This is a novel IVD with no predicate device. The test is for a high-acuity clinical condition (sepsis), but the test itself is a lateral flow assay — a well-understood technology platform. The novelty is in the biomarker, not the platform.

Correct pathway: De Novo is likely the best fit if the device can be classified as Class II with appropriate special controls (clinical performance criteria, analytical validation requirements, labeling). However, if the FDA determines that the clinical consequences of a false negative (missed sepsis) are too severe for Class II controls, they may require PMA. A Pre-Submission meeting is critical to resolve this question before committing resources.

Scenario 8: Orthopedic Spinal Fusion Cage (Iteration of Existing Design)

Situation: A company manufactures 510(k)-cleared PEEK interbody spinal fusion cages (Class II). They want to introduce a new size variant with the same material, same manufacturing process, and same intended use — just different dimensions to accommodate different vertebral anatomies.

Analysis: The company already holds a 510(k) clearance for this device type. The modification is limited to dimensional changes with no change in material, manufacturing process, or intended use. Performance testing can demonstrate equivalent mechanical properties at the new dimensions.

Correct pathway: Special 510(k) referencing the company's own prior clearance. The design controls documentation should include updated risk analysis covering the dimensional change and mechanical testing at the new dimensions. This is a textbook Special 510(k) use case with a 30-day review target.

What Happens When You Choose the Wrong Pathway

Choosing the wrong pathway is not merely an inconvenience — it is a potentially company-ending mistake for startups and a significant financial loss for established companies.

Filing a 510(k) When PMA Is Required

If you submit a 510(k) for a device that should go through PMA, the FDA will either:

• Issue an RTA if it is obvious from the submission that no valid predicate exists or the device is classified under a PMA regulation
• Complete the review and issue a Not Substantially Equivalent (NSE) determination — automatically classifying your device as Class III and requiring a PMA or De Novo

Consequences: You lose 3-6 months in review time, the user fee is non-refundable, and you must now pivot to PMA (adding years and millions of dollars) or De Novo. The NSE determination is a public record.

Filing a PMA When 510(k) or De Novo Would Suffice

This is less common but happens when manufacturers overestimate the risk classification or are unaware of existing predicates or the De Novo option.

Consequences: You spend years and millions on clinical trials and regulatory filings that were not necessary. While the device will eventually reach market, the opportunity cost is enormous — competitors with better regulatory intelligence may reach market years ahead of you with 510(k)-cleared alternatives.

The FDA's Reclassification Authority

The FDA has the authority to reclassify devices — either upgrading (Class II to Class III, requiring PMA) or downgrading (Class III to Class II, allowing 510(k)). Since the Medical Device Amendments of 1976, the FDA has eliminated the use of over 1,750 devices as predicates through reclassification actions. This means your predicate strategy can be disrupted at any time if the FDA determines that a device type's risk profile warrants reclassification.

Practical tip: Before committing to a pathway, always verify that your intended predicate has not been the subject of an FDA reclassification action or call-for-PMA order. Check the Federal Register and FDA's Classification Database for recent changes to your product code's classification status.

Annual Volume and Success Rates: By the Numbers

Understanding the volume and success rates for each pathway provides useful context for planning purposes.

Annual Submission and Authorization Volume

Metric	510(k)	PMA	De Novo
Submissions received per year	~4,000-4,500	~80-120 (original PMAs)	~250-350
Authorizations granted per year	~3,200-3,500 clearances	~40-60 original approvals	~50-80 grants
Percentage of total FDA device authorizations	~56%	~1-2% (original approvals)	~2-3%
RTA / RTF rate	~15-25% (RTA)	~5-10% (RTF)	~15-20% (refuse to accept)
Median calendar days to decision	~130 days	~12-18 months	~250 days

PMA Supplement Volume

In addition to original PMA approvals, the FDA reviews a substantial volume of PMA supplements each year — approximately 1,500-2,000 supplements annually. These include panel-track supplements, 180-day supplements, real-time supplements, and 30-day notices for modifications to PMA-approved devices. This ongoing supplement activity represents a significant portion of CDRH's review workload and reflects the operational burden of maintaining PMA-approved devices.

Success Rates

Exact clearance and approval rates are difficult to calculate precisely because many submissions are withdrawn before a final decision. However, the available data suggests:

• 510(k): Approximately 85-90% of 510(k) submissions that complete review (not withdrawn) receive an SE determination. The NSE rate for fully reviewed submissions is approximately 2-5%.
• PMA: Historically, approximately 70-85% of original PMA applications that are filed (not refused to file) eventually receive approval, though the timeline may include multiple AI rounds and major deficiency cycles.
• De Novo: The grant rate for De Novo requests that complete review has varied significantly as the program has matured. Recent years have shown improving grant rates as both industry and FDA have gained experience with the pathway.

Recall Rates: What Post-Market Data Reveals About Pathway Safety

One of the most debated questions in medical device regulation is whether the 510(k) pathway's reliance on substantial equivalence — rather than independent clinical evidence — leads to higher recall rates compared to PMA-approved devices. Published research provides informative, if imperfect, data.

A comprehensive review published in the Journal of Surgical Research analyzed approvals and recalls across multiple surgical specialties and found that devices cleared through the 510(k) pathway were 5.32 times more likely to be recalled than those approved through PMA. For obstetrics and gynecology devices specifically, the recall rate was 13.6 times higher for 510(k)-cleared devices compared to PMA-approved devices.

However, this data requires careful interpretation:

• Volume effect: Approximately 3,200-3,500 devices are cleared through 510(k) each year, compared to only 40-60 original PMA approvals. The vastly larger number of 510(k) devices on the market naturally produces a higher absolute recall count. The odds ratio accounts for this to some extent, but the underlying device populations are not comparable in risk profile — PMA devices are inherently higher-risk.
• Time-to-recall difference: PMA-approved devices in cardiology remained on the market an average of 94 months before recall, compared to 34 months for 510(k) devices. This could suggest that PMA's more rigorous pre-market review catches early-failure modes before market entry, or it could reflect differences in post-market surveillance intensity.
• Recall class distribution: Most device recalls are Class II recalls (potential for temporary or reversible health consequences), not Class I recalls (potential for serious adverse health consequences or death). The pathway's influence on the severity of recalls, not just the frequency, is a more meaningful safety metric.

The most recalled device categories in the 510(k) pathway include electrosurgical cutting and coagulation devices (22.7%), powered laser surgical instruments (9.1%), and implantable staples (5.8%). For PMA devices, the most recalled categories include saline-inflatable breast prostheses (17.5%), dermal implants for aesthetic use (17.5%), and interactive wound and burn dressings (15.0%).

Practical tip: The recall rate difference does not mean 510(k) is an "unsafe" pathway. It reflects the structural difference in evidentiary standards — PMA requires extensive pre-market clinical testing that identifies many failure modes before commercial distribution, while 510(k) relies on post-market surveillance to identify issues with cleared devices. When evaluating your pathway choice, consider this: if your device type has a history of recalls in the 510(k) pathway, the FDA may impose additional testing requirements or steer you toward a more rigorous pre-market evidence standard.

Liability and Federal Preemption: A Critical Legal Difference

One frequently overlooked difference between PMA and 510(k) is the legal protection each pathway provides against product liability lawsuits. This distinction can have significant financial implications for manufacturers.

PMA and Federal Preemption

PMA-approved devices benefit from a legal doctrine known as federal preemption under the Supreme Court's landmark ruling in Riegel v. Medtronic (2008). The Court held that because PMA involves a device-specific, rigorous federal review of safety and effectiveness, state-law tort claims that would impose requirements "different from, or in addition to" the federal PMA requirements are preempted. In practical terms, this means patients generally cannot sue PMA device manufacturers under state product liability law for design defects or failure-to-warn claims — as long as the manufacturer complied with the FDA-approved specifications and labeling.

This federal preemption provides significant liability protection for PMA device manufacturers, effectively shielding them from many categories of state-law litigation.

510(k) and the Absence of Preemption

510(k)-cleared devices do not receive federal preemption. In Medtronic v. Lohr (1996), the Supreme Court held that 510(k) clearance is not a device-specific safety and effectiveness determination — it is a substantial equivalence finding. Because the FDA does not independently evaluate the safety and effectiveness of a 510(k) device, state-law tort claims are not preempted. Patients can bring state product liability lawsuits (design defect, manufacturing defect, failure to warn) against manufacturers of 510(k)-cleared devices.

Strategic Implications

For device manufacturers, this legal distinction can factor into pathway strategy — particularly for devices that will be used in high-acuity clinical settings where adverse events may lead to litigation. The liability protection afforded by PMA approval represents a non-trivial long-term financial benefit that partially offsets the higher upfront cost of the PMA pathway.

Practical tip: While federal preemption is a real benefit of PMA, it is not absolute. Claims based on violation of federal requirements (e.g., manufacturing a device that deviates from the PMA-approved specifications) are not preempted. Additionally, the preemption landscape continues to evolve through court decisions. Consult with regulatory counsel and product liability counsel when evaluating the legal implications of your pathway choice.

Impact on Product Development Strategy

Your pathway choice does not merely affect the regulatory filing — it shapes your entire product development program from the earliest design stages.

510(k) Development Impact

The 510(k) pathway supports faster development cycles and more iterative product design:

• Design controls scope — While design controls (21 CFR 820.30) apply to all Class II and III devices, the scope of the design history file (DHF) for a 510(k) device is typically narrower because the testing program is calibrated against the predicate rather than against absolute performance criteria.
• Prototyping and iteration — With a shorter regulatory timeline, manufacturers can afford more design iterations before committing to a final design for submission. The faster path to market also allows for post-market design improvements through new 510(k) submissions or letter-to-file changes.
• Verification and validation (V&V) — The V&V program is scoped to demonstrate substantial equivalence. If your predicate was cleared with specific performance tests, your V&V program mirrors those tests. This reduces the scope of testing compared to PMA.
• Release cycle cadence — 510(k) devices can sustain faster product update cycles because modifications can often be implemented via letter-to-file or Special 510(k) (30-day review). Some manufacturers release annual product updates for 510(k)-cleared devices.

PMA Development Impact

The PMA pathway demands a longer, more front-loaded development program:

• Design freeze timing — Because the PMA clinical trial must use the final device design, you must reach a design freeze much earlier in the development process. Design changes after IDE approval may require IDE supplements, protocol amendments, or study restarts.
• Clinical trial integration — Product development and clinical development must run in parallel. Engineering, clinical affairs, regulatory, quality, and manufacturing teams must coordinate from the beginning to ensure the device used in clinical trials is identical to the device described in the PMA application.
• Manufacturing readiness — Your manufacturing process must be validated and inspection-ready before PMA submission because the pre-approval inspection will evaluate your production capabilities. This means manufacturing scale-up must begin well before FDA approval, representing a significant capital investment with no guarantee of approval.
• Supplier controls — PMA devices face heightened scrutiny of the supply chain. Component suppliers must be qualified and controlled per your quality system, and changes to critical suppliers after PMA approval typically require a PMA supplement.

Development Timeline Comparison

Development Phase	510(k) Device	PMA Device
Concept to design freeze	6-18 months	12-36 months
V&V testing	2-6 months	6-18 months
Clinical trial (if needed)	6-18 months (rare)	1-5+ years
Manufacturing validation	2-4 months	6-12 months
Submission preparation	2-6 months	6-18 months
Regulatory review	4-6 months	10-18 months
Total concept to market	12-24 months (typical)	3-7+ years

Practical tip: For PMA-track devices, establish a cross-functional core team (regulatory, clinical, engineering, quality, manufacturing) from the concept stage. The interdependencies between design controls, clinical trial design, manufacturing validation, and the PMA submission require tight coordination that cannot be bolted on late in development.

Real-World Evidence (RWE): An Evolving Factor in Both Pathways

The FDA has increasingly embraced Real-World Evidence (RWE) — evidence generated from real-world data (RWD) such as patient registries, electronic health records, insurance claims data, and post-market surveillance — as a complement to traditional clinical trial data for both 510(k) and PMA submissions.

How RWE Is Used in Each Pathway

510(k) submissions: RWE can support a 510(k) by providing clinical performance data for the predicate device or for the subject device through post-market experience. Literature reviews of published real-world clinical studies are a common form of RWE in 510(k) submissions. When FDA guidance calls for clinical data but a full prospective trial is disproportionate to the device risk, a well-designed retrospective analysis of registry or claims data may satisfy the clinical evidence requirement.

PMA submissions: The FDA has accepted RWE as the primary clinical evidence in certain PMA supplements, particularly for expanded indications. For example, several transcatheter heart valve PMA supplements have relied on data from the STS/ACC Transcatheter Valve Therapy (TVT) Registry, linked with CMS administrative claims data, to support indication expansions and post-approval surveillance. The FDA has published over 90 examples of RWE used in regulatory decision-making, spanning 510(k), De Novo, HDE, and PMA submissions.

Post-approval studies: For PMA-approved devices with conditions of approval requiring long-term follow-up, RWE from registries can serve as the data source for post-approval studies (PAS). This can be significantly less expensive than conducting a dedicated prospective post-approval clinical trial.

When RWE May Be Appropriate

• When clinical trial enrollment is impractical due to disease rarity or ethical constraints on randomization
• For expanded indications where the device's safety profile is well-established from prior clinical use
• For long-term safety follow-up where registry data provides adequate endpoint capture
• When existing registry infrastructure captures the relevant clinical outcomes

Practical tip: If you are considering an RWE-based regulatory strategy, discuss it with the FDA in a Pre-Submission meeting before committing resources. The FDA evaluates RWE on a case-by-case basis, and the acceptability of RWD sources, study designs, and endpoints varies by device type and clinical context. The FDA's guidance document "Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices" provides the framework for evaluating RWE quality and applicability.

Frequently Asked Questions

Can a device ever go through both 510(k) and PMA?

Not simultaneously, but sequentially — yes. If a 510(k) submission receives an NSE determination, the manufacturer can subsequently file a PMA or De Novo for the same device. Additionally, the FDA can reclassify a device type from Class II (510(k)) to Class III (PMA), requiring existing manufacturers to file PMAs for devices they previously marketed under 510(k) clearance.

Is a 510(k) "less safe" than a PMA because it does not require clinical trials?

Not necessarily. The 510(k) is premised on the assumption that if a device is substantially equivalent to a legally marketed device with a known safety profile, additional clinical evidence may not be needed. Many Class II devices are well-understood technologies where decades of post-market experience have established the safety profile. The PMA requirement reflects higher inherent risk and the absence of a comparable marketed device — not a qualitative judgment that 510(k) review is insufficient.

How many 510(k) submissions include clinical data?

Approximately 10-15% of 510(k) submissions include some form of clinical data. This can range from a published literature review to a prospective clinical study. The percentage varies significantly by device type — orthopedic implants, cardiovascular devices, and certain IVDs are more likely to require clinical data than general-purpose medical equipment.

Can I convert a PMA application to a 510(k) if I find a predicate during the review?

Generally not during active review. If you discover a suitable predicate after filing a PMA, the typical approach is to withdraw the PMA and file a 510(k), or discuss the situation with the FDA during the Day 100 meeting or through a Submission Issue Request (SIR). The FDA may suggest that you withdraw and refile, but it will not convert one submission type to another.

What is a "pre-amendment" Class III device, and why can some be marketed through 510(k)?

Pre-amendment devices are device types that were on the market before the Medical Device Amendments of 1976. Some Class III device types have not yet been subject to an FDA "call for PMA" — meaning the FDA has not issued a final regulation requiring PMA for that device type. Until the FDA issues such an order, these Class III devices can be marketed through 510(k) by demonstrating substantial equivalence to a pre-amendment device. This is a shrinking category as the FDA continues to issue call-for-PMA orders.

Does Breakthrough Device Designation guarantee faster review?

No. Breakthrough designation provides more interactive FDA engagement, flexible study design discussions, and priority review, but the standard premarket processes (PMA, 510(k), De Novo) still apply. Empirical data suggests an average review-time savings of approximately 75 days — significant but not transformative. The real value of Breakthrough designation is in the study design flexibility and the CMS TCET coverage pathway, not simply faster review.

Can foreign clinical data support a PMA application?

Yes. The FDA accepts foreign clinical data to support a PMA, provided the studies were conducted in accordance with good clinical practice (GCP) and the data are applicable to the US population. The FDA's guidance on "Acceptance of Clinical Data to Support Medical Device Applications and Submissions" addresses the standards for foreign data acceptance.

What is the annual cost of maintaining a PMA vs. a 510(k) post-clearance/approval?

For 510(k)-cleared devices, the annual cost is primarily the establishment registration fee ($11,423 for FY2026) plus quality system maintenance. For PMA-approved devices, add the cost of preparing the annual report, conducting any required post-approval studies (potentially millions per year), and the regulatory overhead of PMA supplement filings for device modifications. The ongoing regulatory cost of maintaining a PMA can be $500K-$2M+ per year, compared to negligible incremental regulatory cost for a 510(k) beyond baseline quality system compliance.

How does the Humanitarian Device Exemption (HDE) differ from PMA?

The Humanitarian Device Exemption (HDE) is an alternative pathway for devices intended to benefit patients with rare conditions (affecting fewer than 8,000 individuals per year in the US). An HDE application is similar in form to a PMA but does not require clinical evidence of effectiveness — only safety. The FDA must find a probable benefit that outweighs the risk. HDE-approved devices carry specific restrictions, including a requirement that they be used in facilities with an Institutional Review Board (IRB) that has approved the use of the device. HDE user fees are substantially lower than PMA user fees.

Can I use a Predicate Submission (PS) approach for my first submission?

There is no formal "predicate submission" pathway. However, the concept of choosing a predicate wisely is foundational to 510(k) strategy. If you are a first-time submitter, you must identify at least one legally marketed predicate device. You can use any legally marketed device as a predicate — it does not have to be your own. However, if you want to use a Special 510(k) (the fastest review type at 30 days), you can only reference your own prior clearance. For first-time submitters, a Traditional or Abbreviated 510(k) is the only option.

What role does Quality System (QMS) compliance play in each pathway?

Both pathways require compliance with the FDA's Quality System Regulation (21 CFR Part 820, transitioning to the Quality Management System Regulation / QMSR that aligns with ISO 13485). However, the practical implications differ. For PMA devices, the FDA conducts a pre-approval inspection (PAI) of your manufacturing site before issuing approval — meaning your QMS must be fully implemented and producing compliant results before you can receive PMA approval. For 510(k) devices, there is no pre-clearance inspection requirement, though the FDA can (and does) inspect 510(k) manufacturers at any time after clearance. In practice, many startups begin manufacturing before their QMS is fully mature when pursuing a 510(k), whereas PMA manufacturers must have a mature, inspection-ready QMS before they can receive their approval.

How do I find out which pathway my competitors used?

All FDA clearances and approvals are public records. You can search the following databases:

• 510(k) Premarket Notification Database (accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm) — Search by applicant name, device name, or product code to find competitors' 510(k) clearances and their predicate devices
• PMA Database (accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm) — Search for approved PMAs including supplements
• De Novo Decision Summary Database — Search for granted De Novo classifications
• Product Classification Database — Look up the classification regulation, product code, and required premarket submission type for your device category

Reviewing competitors' clearances and approvals reveals their pathway strategy, predicate choices (for 510(k)), testing approach (from 510(k) summaries and PMA SSEDs), and labeling — all of which inform your own regulatory strategy.

Can I submit a 510(k) while a PMA is under review, or vice versa?

You cannot have two active premarket submissions for the same device at the same time. However, if you receive an NSE determination on a 510(k), you can subsequently file a De Novo or PMA. If you want to change pathways mid-development (e.g., switch from PMA to De Novo because you determine the device is lower risk than initially assessed), you should discuss this with the FDA in a Pre-Submission meeting before withdrawing one application and filing another.

Do all medical devices require FDA clearance or approval before marketing?

No. Most Class I devices (approximately 95%) are exempt from the 510(k) requirement and can be marketed after completing establishment registration and device listing without any premarket submission. Some Class II devices are also 510(k)-exempt. However, all device manufacturers — regardless of classification — must comply with general controls including establishment registration, device listing, quality system requirements, labeling regulations, and adverse event reporting. Devices that are 510(k)-exempt still require FDA registration; they simply skip the premarket notification step.

What happens if my 510(k) submission is rejected?

If the FDA issues a Refuse to Accept (RTA) letter, your submission is returned without substantive review. You must address the deficiencies identified in the RTA letter and resubmit — paying a new user fee unless the resubmission occurs within the same fiscal year and qualifies under certain fee provisions. If the FDA completes review and issues a Not Substantially Equivalent (NSE) determination, your device is automatically classified as Class III. You can then pursue a De Novo classification request (if the device is low-to-moderate risk) or a PMA application. In either case, you cannot legally market the device until you obtain an appropriate authorization.

Can a manufacturer voluntarily choose PMA even if 510(k) is available?

Yes. A manufacturer may choose to pursue PMA for a device that qualifies for 510(k) clearance. While this is uncommon because of the dramatically higher cost and longer timeline, there are strategic reasons to do so — including the federal preemption liability protection that PMA provides (under Riegel v. Medtronic), the marketing advantage of being able to say "FDA approved" rather than "FDA cleared," and the ability to generate clinical data that supports stronger reimbursement arguments. However, this is a rare strategic choice that should be evaluated carefully against the additional cost and timeline burden.

What percentage of medical devices reach the US market through 510(k)?

Over 80% of medical devices currently on the US market were cleared through the 510(k) pathway. Each year, the FDA clears approximately 3,200-3,500 devices through 510(k), compared to only 40-60 original PMA approvals. The 510(k) pathway handles the vast majority of Class II devices, which represent the largest category of regulated medical devices.

Is FDA registration the same as FDA clearance or approval?

No. FDA registration (establishment registration and device listing under 21 CFR Part 807) is a prerequisite for all device manufacturers — it means your facility and devices are listed in the FDA's database. Registration is an administrative requirement, not a safety or effectiveness determination. FDA clearance (510(k)) and FDA approval (PMA) are separate premarket review processes where the FDA evaluates your device before authorizing marketing. You must be registered before submitting a 510(k) or PMA, but registration alone does not authorize you to market a device that requires premarket review.

Key Takeaways

1. The evidentiary standard is fundamentally different. The 510(k) requires substantial equivalence to a predicate. PMA requires an independent demonstration of reasonable assurance of safety and effectiveness. This is not a matter of degree — it is a different legal question with different evidence expectations, different labeling consequences, and different post-market obligations.

2. Cost and timeline differ by orders of magnitude. A 510(k) typically costs $50K-$500K and takes 6-18 months. A PMA typically costs $5M-$75M+ and takes 3-7+ years including clinical trials. This drives every business decision from fundraising to competitive strategy to hiring plans. Know your pathway before you build your business plan.

3. De Novo is not a compromise — it is often the right answer. If your device is novel but low-to-moderate risk, De Novo avoids PMA's cost and timeline while establishing a new classification regulation. It is the strategically correct pathway for many digital health, AI/ML, and novel diagnostic devices. A successful De Novo creates a predicate for future 510(k) submissions — which may benefit or disadvantage your competitive position depending on your market strategy.

4. Post-market obligations differ substantially. PMA-approved devices require annual reports, often require post-approval studies costing millions per year, and impose structured supplement requirements for every device modification. 510(k)-cleared devices have no annual reporting requirement, no mandatory post-approval studies, and more flexible change management through letter-to-file determinations.

5. Pathway choice affects international strategy. PMA approval carries more credibility with international regulators because it is based on independent clinical evidence. 510(k) clearance based on substantial equivalence may receive less weight in markets that require independent evidence of safety and effectiveness. Clinical trial data generated for a PMA can typically be repurposed for EU MDR, Japanese, and other international submissions.

6. Pre-Submission meetings are essential for both pathways. The FDA's Q-Sub program lets you align your strategy with FDA expectations before investing in testing or clinical trials. Use it — there is no user fee for Pre-Submissions and the feedback can save you months of rework and hundreds of thousands in unnecessary testing.

7. Choosing the wrong pathway can be catastrophic. An NSE determination on a 510(k) adds years and millions to your program. An unnecessary PMA wastes resources on clinical trials that were never required. Invest the time upfront to search the classification database, review competitors' regulatory history, and consult with the FDA through a Pre-Submission meeting.

8. Breakthrough Device Designation is a tool, not a shortcut. It provides meaningful benefits — interactive FDA engagement, flexible study design, priority review, and CMS TCET coverage eligibility — but it does not bypass the standard premarket process. Apply early in development to maximize the benefit of FDA input on study design and endpoints.

9. Change management has long-term cost implications. For 510(k) devices, product improvements can often be implemented after a letter-to-file determination with no FDA submission required. For PMA devices, even minor modifications may require a PMA supplement with a review period of 30 to 180 days. Over a product's lifecycle, this difference can add up to hundreds of thousands of dollars in regulatory overhead and months of delayed product updates.

10. Your QMS must be ready on a different timeline for each pathway. For PMA devices, your quality system must pass an FDA pre-approval inspection before you receive approval. For 510(k) devices, your QMS must be compliant from the moment you begin commercial distribution, but there is no pre-clearance inspection gate. Plan your QMS implementation timeline accordingly.